rupiya.io
⠋Loading...
0%
❯ Fetching latest market data...
Aurobindo Pharma Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Aurobindo Pharma Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹8,089 Cr | ₹12,103 Cr | ₹13,772 Cr | |||||||||
| Expenses | ₹5,951 Cr | ₹9,524 Cr | ₹10,579 Cr | |||||||||
| Operating Profit | ₹2,137 Cr | ₹2,579 Cr | ₹3,193 Cr | |||||||||
| OPM % | 26.0% | 21.0% | 23.0% | |||||||||
| Other Income | ₹18 Cr | ₹81 Cr | ₹200 Cr | |||||||||
| Depreciation | ₹313 Cr | ₹333 Cr | ₹392 Cr | |||||||||
| Interest | ₹310 Cr | ₹160 Cr | ₹257 Cr | |||||||||
| Profit Before Tax | ₹1,533 Cr | ₹2,168 Cr | ₹2,744 Cr | |||||||||
| Tax | ₹1,533 Cr | ₹2,168 Cr | ₹2,744 Cr | |||||||||
| Net Profit | ₹1,169 Cr | ₹1,571 Cr | ₹2,024 Cr | |||||||||
| EPS (₹) | 20.1 | 27.0 | 34.6 | |||||||||
| Dividend Payout % | 7% | 8% | 7% |
Register free to see 9 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹6,407 Cr | ₹6,473 Cr | ₹6,851 Cr | ₹7,219 Cr | ||||||||
| Expenses | ₹5,453 Cr | ₹5,477 Cr | ₹5,702 Cr | ₹5,846 Cr | ||||||||
| Operating Profit | ₹954 Cr | ₹996 Cr | ₹1,149 Cr | ₹1,373 Cr | ||||||||
| OPM % | 15.0% | 15.0% | 17.0% | 19.0% | ||||||||
| Depreciation | ₹321 Cr | ₹346 Cr | ₹327 Cr | ₹418 Cr | ||||||||
| Interest | ₹45 Cr | ₹56 Cr | ₹57 Cr | ₹68 Cr | ||||||||
| Net Profit | ₹491 Cr | ₹506 Cr | ₹570 Cr | ₹752 Cr | ||||||||
| EPS (₹) | 8.4 | 8.6 | 9.7 | 12.9 |
Register free to see 8 more quarters.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹29 Cr | ₹29 Cr | ₹59 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹3,721 Cr | ₹5,127 Cr | ₹7,229 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹3,769 Cr | ₹4,451 Cr | ₹5,041 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹1,970 Cr | ₹3,303 Cr | ₹3,568 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹9,490 Cr | ₹12,910 Cr | ₹15,896 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹2,722 Cr | ₹3,706 Cr | ₹4,180 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹20 Cr | ₹20 Cr | ₹123 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹6,439 Cr | ₹8,765 Cr | ₹10,745 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹9,490 Cr | ₹12,910 Cr | ₹15,896 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 9 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹646 Cr | ₹-819 Cr | ₹118 Cr | — |
| Mar 2016 | ₹1,237 Cr | ₹-1,017 Cr | ₹93 Cr | — |
| Mar 2017 | ₹1,420 Cr | ₹-1,446 Cr | ₹365 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 9 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +4.58% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +5.05% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -8.88% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +11.69% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +5.77% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.